JAGX

+ Watchlist + Portfolio

Jaguar Health, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.92
52-Week Range: $0.73 – $85.40
Market Cap: $4.29M
P/E (TTM): —
EPS (TTM): -695.50
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -35.86%
Gross Margin: 85.06%
Operating Margin: 50.23%
Profit Margin: -115.40%
Current Ratio: 0.65
Debt/Equity: —
Total Debt: $34.31M
Free Cash Flow: $-2.09M
Revenue Growth: 815.60%
Earnings Growth: —
Enterprise Value: $35.49M

JAGX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$11.96M	$9.76M	$11.69M	$11.51M
Cost of Revenue	$2.02M	$2.04M	$1.96M	$3.77M
Gross Profit	$9.94M	$7.72M	$9.73M	$7.74M
Research & Development	$17.65M	$18.60M	$16.54M	$24.97M
Selling, General & Admin	$26.70M	$23.05M	$22.18M	$26.02M
Operating Expenses	$44.35M	$41.64M	$40.56M	$52.84M
Operating Income	-$34.41M	-$33.92M	-$30.83M	-$45.11M
EBITDA	-$33.38M	-$33.13M	-$36.66M	-$51.73M
Pretax Income	-$48.40M	-$41.90M	-$39.25M	-$54.00M
Income Tax	$0.00	$0.00	$0.00	$0.00
Net Income	-$47.45M	-$41.30M	-$38.49M	-$53.43M
Diluted EPS	-1129857.14	-29542.20	-4574.15	-803.95
Diluted Shares	42	1398	8415	66640

JAGX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$5.47M	$6.47M	$8.00M	$968.00K
Receivables	$2.47M	$2.18M	$1.65M	$1.70M
Inventory	$7.02M	$9.19M	$10.35M	$8.60M
Current Assets	$22.32M	$27.96M	$32.20M	$20.34M
Total Assets	$47.45M	$50.76M	$53.42M	$38.32M
Current Liabilities	$30.34M	$13.99M	$19.70M	$40.65M
Long-Term Debt	$17.74M	$30.99M	$23.50M	$15.08M
Total Debt	$34.84M	$37.09M	$36.53M	$43.61M
Total Liabilities	$48.81M	$45.87M	$46.93M	$57.01M
Retained Earnings	-$266.95M	-$308.25M	-$346.48M	-$399.92M
Shareholders' Equity	-$657.00K	$4.96M	$7.29M	-$17.29M
Working Capital	-$8.02M	$13.98M	$12.49M	-$20.31M
Net Debt	$28.16M	$29.39M	$27.54M	$41.55M

JAGX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$33.10M	-$33.24M	-$29.38M	-$23.69M
Capital Expenditure	-$1.68M	—	-$231.00K	-$41.00K
Free Cash Flow	-$34.78M	-$33.24M	-$29.61M	-$23.73M
Depreciation & Amortisation	$2.29M	$2.39M	$2.36M	$2.20M
Stock-Based Compensation	$3.32M	$2.11M	$1.64M	$831.00K
Investing Cash Flow	-$1.68M	$0.00	-$231.00K	-$41.00K
Financing Cash Flow	$23.18M	$34.23M	$31.20M	$23.67M
Net Change in Cash	-$11.60M	$985.00K	$1.59M	-$57.00K

JAGX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$2.21M	$2.98M	$3.08M	$3.23M	$20.25M
Cost of Revenue	$515.00K	$527.00K	$532.00K	$2.20M	$1.16M
Gross Profit	$1.70M	$2.45M	$2.55M	$1.03M	$19.09M
Research & Development	$3.73M	$3.27M	$3.66M	$14.31M	$3.93M
Selling, General & Admin	$6.91M	$7.19M	$6.13M	$5.31M	$4.54M
Operating Expenses	$11.12M	$10.46M	$9.79M	$21.48M	$8.91M
Operating Income	-$9.42M	-$8.01M	-$7.24M	-$20.44M	$10.18M
EBITDA	-$8.88M	-$7.45M	-$6.68M	-$28.72M	$9.94M
Pretax Income	-$10.60M	-$10.56M	-$9.65M	-$23.19M	$8.72M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$10.46M	-$10.41M	-$9.50M	-$23.06M	$8.85M
Diluted EPS	-584.45	-359.10	-219.80	—	-476.00
Diluted Shares	17903	28993	43233	—	14736

JAGX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$5.69M	$2.21M	$3.53M	$968.00K	$7.28M
Receivables	$1.39M	$1.32M	$1.50M	$1.70M	$280.00K
Inventory	$10.55M	$10.72M	$10.63M	$8.60M	$7.82M
Current Assets	$30.44M	$27.90M	$29.40M	$20.34M	$20.21M
Total Assets	$51.46M	$48.27M	$49.47M	$38.32M	$37.43M
Current Liabilities	$28.21M	$29.22M	$36.12M	$40.65M	$40.69M
Long-Term Debt	$18.43M	$10.74M	$7.65M	$15.08M	$11.07M
Total Debt	$38.34M	$30.53M	$31.90M	$43.61M	$43.78M
Total Liabilities	$50.63M	$41.39M	$45.11M	$57.01M	$53.19M
Retained Earnings	-$356.95M	-$367.35M	-$376.86M	-$399.92M	-$391.07M
Shareholders' Equity	$1.78M	$7.99M	$5.63M	-$17.29M	-$14.18M
Working Capital	$2.23M	-$1.31M	-$6.72M	-$20.31M	-$20.48M
Net Debt	$31.38M	$27.11M	$27.23M	$41.55M	$35.34M

JAGX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$7.31M	-$6.20M	-$4.69M	-$5.49M	$8.83M
Free Cash Flow	-$7.31M	-$6.20M	-$4.74M	-$5.47M	$8.83M
Depreciation & Amortisation	$546.00K	$556.00K	$557.00K	$543.00K	$520.00K
Stock-Based Compensation	$301.00K	$279.00K	$135.00K	$116.00K	$155.00K
Investing Cash Flow	—	—	-$54.00K	$13.00K	—
Financing Cash Flow	$4.97M	$2.65M	$6.26M	$9.79M	-$6.62M
Net Change in Cash	-$2.35M	-$3.54M	$1.52M	$4.32M	$2.21M

Market Snapshot

About

Jaguar Health, Inc. is a commercial-stage pharmaceuticals company focused on developing plant-based prescription medicines for gastrointestinal distress. The company markets Mytesi, a prescription medicine for the symptomatic relief of diarrhea in adults living with HIV/AIDS on antiretroviral therapy. Jaguar is also developing Crofelemer for additional indications including cancer therapy-related diarrhea and congenital diarrheal disorders. The company leverages sustainable botanical ingredients from South American rainforests in its drug development efforts.